P. Palese

Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate AVX/COVID-12 Activates T Cells and Is Recognized by Antibodies from COVID-19 Patients and Vaccinated

This paper evaluates the AVX/COVID-12 vaccine's ability to activate T cells and bind antibodies from vaccinated individuals and SARS-CoV-2-infected patients.

Antigenic landscape analysis of individuals vaccinated with a universal influenza virus vaccine candidate reveals induction of cross-subtype immunity

The paper analyzes immune responses to a universal influenza vaccine using a microarray to show broad antibody coverage against group 1 hemagglutinins.

Trivalent NDV-HXP-S vaccine protects against phylogenetically distant SARS-CoV-2 variants of concern in mice

The paper tests a trivalent NDV-HXP-S vaccine against SARS-CoV-2 variants in mice, showing increased protection and cross-neutralizing antibodies against Omicron.

Discovery of a SARS-CoV-2 Broadly-Acting Neutralizing Antibody with Activity against Omicron and Omicron + R346K Variants

This paper identifies a broadly neutralizing antibody, STI-9167, effective against SARS-CoV-2 variants including Omicron and Omicron + R346K, and describes its development for clinical trials.

A Newcastle disease virus-vector expressing a prefusion-stabilized spike protein of SARS-CoV-2 induces protective immune responses against prototype virus and variants of concern in mice and hamsters

This study develops a Newcastle disease virus-based vaccine expressing a prefusion-stabilized SARS-CoV-2 spike protein, showing strong immune responses and cross-neutralization against variants in mice and hamsters.

Prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine.

This study shows that a live attenuated influenza virus vaccine lacking NS1 provides broad protection against respiratory viruses including SARS-CoV-2 by inducing both innate and adaptive immune responses.

An egg-derived sulfated N-Acetyllactosamine glycan is an antigenic decoy of influenza virus vaccines

This study identifies an egg-derived sulfated N-Acetyllactosamine glycan in influenza vaccines that acts as an antigenic decoy, inducing antibodies that may reduce immune response to protective epitopes.

A public broadly neutralizing antibody class targets a membrane-proximal anchor epitope of influenza virus hemagglutinin

This study identifies a class of broadly neutralizing antibodies targeting a conserved membrane-proximal epitope on influenza HA, showing their induction by a chimeric HA vaccine.

A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine

This paper evaluates an inactivated Newcastle disease virus expressing the SARS-CoV-2 spike protein as a cost-effective vaccine, showing immunogenicity and protective efficacy in animal models.

Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as vaccine candidate

This paper describes NDV vector vaccines expressing SARS-CoV-2 spike protein that protect mice from viral challenge and can be produced cost-effectively in chicken eggs.